Last reviewed · How we verify

peribulbar block 1 lidocaine/bupivacaine — Competitive Intelligence Brief

peribulbar block 1 lidocaine/bupivacaine (peribulbar block 1 lidocaine/bupivacaine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic. Area: Anesthesiology.

phase 3 Local anesthetic Voltage-gated sodium channels Anesthesiology Small molecule Live · refreshed every 30 min

Target snapshot

peribulbar block 1 lidocaine/bupivacaine (peribulbar block 1 lidocaine/bupivacaine) — Centro Medico Docente la Trinidad. Lidocaine and bupivacaine work by blocking sodium channels in nerve fibers, preventing the transmission of pain signals.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
peribulbar block 1 lidocaine/bupivacaine TARGET peribulbar block 1 lidocaine/bupivacaine Centro Medico Docente la Trinidad phase 3 Local anesthetic Voltage-gated sodium channels
Propofol/Lidocaine Propofol/Lidocaine NYU Langone Health marketed Intravenous anesthetic combination GABA-A receptor (propofol); voltage-gated sodium channels (lidocaine)
ESL ESL Bial - Portela C S.A. marketed Voltage-gated sodium channel blocker; anticonvulsant Voltage-gated sodium channels (Nav)
Exparel TAP + multi-modal pain regimen Exparel TAP + multi-modal pain regimen Pacira Pharmaceuticals, Inc marketed Local anesthetic (liposomal formulation) Voltage-gated sodium channels
carbamazepine ER (Equetro) carbamazepine ER (Equetro) Massachusetts General Hospital marketed Anticonvulsant; mood stabilizer Voltage-gated sodium channels
Suzetrigine (SUZ) Suzetrigine (SUZ) Vertex Pharmaceuticals Incorporated marketed Selective sodium channel inhibitor Voltage-gated sodium channels (Nav)
Exparel + Bupivacaine Exparel + Bupivacaine Pacira Pharmaceuticals, Inc marketed Local anesthetic (liposomal formulation) Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic class)

  1. University of California, San Diego · 3 drugs in this class
  2. Durect · 3 drugs in this class
  3. Pacira Pharmaceuticals, Inc · 3 drugs in this class
  4. Wake Forest University Health Sciences · 3 drugs in this class
  5. Medical University of Vienna · 3 drugs in this class
  6. Imperial College London · 2 drugs in this class
  7. Hvidovre University Hospital · 2 drugs in this class
  8. Innocoll · 2 drugs in this class
  9. George Washington University · 2 drugs in this class
  10. Guy's and St Thomas' NHS Foundation Trust · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). peribulbar block 1 lidocaine/bupivacaine — Competitive Intelligence Brief. https://druglandscape.com/ci/peribulbar-block-1-lidocaine-bupivacaine. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: